The collaboration will begin with a pilot program in rural Colorado utilizing Nuvo’s INVU distant monitoring system, which was cleared by the FDA final 12 months. The businesses say this system may enhance entry to maternity care in rural communities, the place a lack of choices contributes to worse outcomes and better mortality charges.
“Digital options and ecosystem-building are important enablers to addressing disparities in healthcare akin to entry to maternal well being care in rural settings,” Sandra Lesenfants, common supervisor, hospital affected person monitoring, at Philips, mentioned in a press release. “With this collaboration, we’re extending the sight and attain of being pregnant care and bringing extra distant monitoring choices to the communities and expectant moms the place and once they want them most.”
Prescription digital therapeutics firm Pear Therapeutics will now be accessible in Epic’s App Orchard Gallery, permitting suppliers to observe sufferers utilizing the corporate’s therapeutics inside the EHR.
Together with the PearConnect service platform within the gallery will enhance workflows for suppliers as they handle sufferers utilizing reSET or reSET-O for substance use and opioid use issues, the corporate mentioned. They will have the ability to evaluate affected person progress and doc distant monitoring work for reimbursement.
“We’re excited to deliver this chance to broaden entry to our PDTs, with the preliminary itemizing of our PearConnect platform within the App Orchard gallery to assist reSET and reSET-O sufferers. We imagine Pear’s integration with Epic will create a pathway for healthcare suppliers to simply entry our PearConnect platform and allow scale to serve many extra sufferers,” Pear chief business officer Julia Strandberg mentioned in a press release.
Digital actuality therapeutics startup AppliedVR introduced it has modified the identify of its EaseVRx therapeutic to RelieVRx.
The system acquired FDA De Novo clearance to deal with continual decrease again ache in November. AppliedVR plans to launch the rebranded RelieVRx in just a few markets this 12 months to organize for its full launch in 2023.
“Whereas ease of use is certainly an necessary a part of our design, in the end we needed a reputation that higher mirrored how our progressive product intends to supply life-changing aid. With demonstrated efficacy knowledge, ‘RelieVRx’ higher captures the core good thing about ache aid that the healthcare trade is on the lookout for: a prescription therapy possibility that gives a novel modality whereas addressing unmet affected person wants,” cofounder and CEO Matthew Stoudt mentioned in a press release.
The corporate additionally introduced it had appointed Dr. Charisse Y. Sparks as chief medical officer to assist the RelieVRx launch and its potential enlargement for different scientific wants. Sparks most not too long ago labored at DePuySynthes, the orthopedic system arm of Johnson & Johnson.
“Racial, ethnic and financial disparities in continual ache administration are properly established. Dependable research present that these disparities present up within the undertreatment of ache in addition to overdose deaths, which proceed to extend,” Sparks mentioned in a press release. “I’m wanting ahead to creating immersive therapeutics a typical of care in continual ache administration and establishing AppliedVR as a pacesetter in well being fairness for the digital well being trade.”